Soaring Prescription Drug Prices
As nurses, we take pride in our concern about the ''whole patient.'' Thus, it stands to reason that an essential part of nursing care, regardless of setting or specialty, is knowing how patients pay for their prescription medications and the extent to which they can afford out of pocket drug costs. It's one thing to give patients a prescription or fax it to a pharmacy. It's another thing to know if they were able to afford and obtain the medication. We have an ethical responsibility to our patients and profession to learn about the economics and politics of prescription drug costs. Let's consider the policies and politics of prescription drug costs and what actions nurses might take in response. Muting our voices in the deliberations on prescription drug pricing would be a serious policy and political oversight.
Payer Variations Among Prescription Drug Policies
Analyzing national data for prescription drug costs presents challenges. Yet, it also can provide insights into the reasons for variations in prescription drug pricing, costs to consumers, and possible policy solutions. A first step is understanding that prescription drug costs and policies are payer dependent, meaning that each payer (e.g., Medicare, Medicaid, other government programs, or private insurers) has its own policies regarding eligibility, co-payments, deductibles, and covered drugs (How to get drug coverage, n.d.; Your Medicare Coverage Choices, n.d.). Furthermore, prescription drug policies differ across options for each payer. For example, the type of Medicare plan one selects-original Medicare or a Medicare Advantage (MA) Plan-affects one's Medicare prescription drug coverage. Beneficiaries enrolled in traditional Medicare who want prescription drug coverage must select a Medicare Part D plan. Beneficiaries enrolled in an MA Plan must obtain prescription drug coverage through that plan, if the plan offers it.
Under federal Medicaid law, states have the option of providing pharmacy benefits. All states have chosen to offer such coverage for outpatient prescription drugs to categorically eligible individuals and most states cover medically needy enrollees within their state Medicaid programs (List of Medicaid eligibility groups, n.d.; ''Medicaid Medically Needy,'' 2012; Prescription Drugs, n.d.) . Furthermore, state Medicaid prescription drug programs vary with regard to policies for drug rebates (Medicaid Drug Rebate Program, n.d.), covered drugs, and pricing. Economists must account for Medicaid prescription drug rebates when analyzing consumer and national prescription drug costs.
Other sources of variation in prescription drug pricing by payer include federal and state exchanges under the Affordable Care Act (ACA), each of which has its own prescription drug coverage prices and policies. Also, large employers typically negotiate with insurance companies for employee prescription drug benefits and out of pocket costs.
Soaring Prices of Prescription Drugs
Steep increases in the prices of prescription drugs have captured the attention of journalists, social media reporters, health-care advocacy groups, think tanks, and state and federal policymakers. But all prescription drugs and pricing mechanisms are not the same. Generic drugs comprise about 80% of all prescriptions. Their lower prices compared with brand drugs have been a major factor in controlling total health-care expenditures and patients' out of pocket health care spending over the past 5 to 10 years (Jaret, 2015) . This is changing. As a reporter for the AARP Bulletin noted, ''Across the country, people . . . are going in to fill prescriptions only to discover that the cost has doubled, tripled and in some cases soared by 1,000 percent or more'' (Jaret, 2015) . Rampant price increases for some generics have surpassed the national inflation rate, ''sometimes by a long shot'' (Jaret, 2015) .
Brand-name drugs generate huge profits for pharmaceutical companies. To ''protect their monopoly'' in brand-name markets, pharmaceutical companies have used ''controversial'' tactics. Some members of Congress have responded by introducing bipartisan bills that restrict pharmaceutical companies from employing such strategies (''Schakowsky, Brown, McCain Introduce Bipartisan Legislation,'' 2016; Statement of Senator Patrick Leahy (D-VT), 2016).
The furor over Mylan's EpiPen's price increase from $100 per pair in 2007 to $600 in 2016 (Clarke, 2016) exemplified how public clamor can prompt government action. Patients, parents of young children, school nurses, and other clinicians protested the exorbitant price increase for a medication and syringe that cost about $35 to manufacture and can mean the difference between life and death in treating severe allergic reactions (Mangan, 2016) . On September 21, 2016, the House Committee on Oversight and Government Reform held hearings at which Mylan's Chief Executive defended her company's price increases given its marketing and research costs, rebates, and free provision of pens to some schools. She also said that Mylan was developing a less expensive form of EpiPen that would soon be on the market.
Although the U.S. Justice Department reached a $465 million settlement with Mylan, the controversy continues because of the lack of transparency over the settlement's terms. There also has been no government action taken to prevent pharmacy companies from hiking prices in the future.
Other prescription drug costs problems exist. For example, special categories of prescription drugs, such as orphan drugs and biologics, have separate pricing issues.
Political Context
Placing prescription drug costs in political context reveals that new laws or regulations often prompt price increases for patients. This is because pharmaceutical executives worry about the possible economic effects of new public policies on their company's bottom line. Prescription medication prices increased with implementation of Medicare Part D, Medicaid's rebate program, and most recently, with regulations pursuant to the ACA (Jaret, 2015) .
Prescription drug costs under the ACA for women using oral contraceptives are an exception to the notion that policy changes prompt price increases.
Notably, the proportion of women facing no cost sharing for oral contraceptives increased from 6% to 92% with the ACA enactment. In contrast, use of any type of prescription contraceptive increased by 2.3 percentage points after the ACA cost-sharing policy went into effect. (Weil, 2016 (Weil, , p. 1555 Interest groups have rallied around the issue of prescription drug costs by forming a coalition, the Campaign for Sustainable Drug Pricing (Campaign for Sustainable Drug Pricing, 2016). The Campaign's organizational members represent clinicians, insurers, employers, health plans, and hospitals. John Rother, President and CEO of the National Coalition on Health Care, leads the Campaign, which operates through the National Coalition on Health Care Action Fund. (Rother was previously Executive Vice President for Policy, Strategy, and International Affairs at AARP. Before that, he held positions as special counsel for major senate committees.)
The most powerful voice against enhanced regulation of prescription drug prices, including allowing the federal government to negotiate Medicare prices, is the pharmaceutical industry. PhRMA represents the nation's leading biopharmaceutical companies, a powerful advocacy entity given its ''more $1.2 trillion in economic output,'' the hundreds of thousands of jobs it creates across the country, and its impact on every state's economy. For example, in New York state, PhRMA was responsible for directly creating nearly 55,000 jobs and indirectly producing over 240,000 jobs (''State Map, Economic Impact,'' n.d.).
Regarding state policies, California had a ballot initiative that voters defeated in the November elections. A vote in favor of California's Proposition 61 would have supported state regulation of drug prices by requiring the state's agencies to pay no more than what that the U.S. Veteran's Affairs pays for prescription drugs. A similar proposition will be on the Ohio ballot in November 2017 (California Proposition 61, 2016) .
Huge amounts of money have been spent for and California Proposal 61, measure, totaling nearly $125 million by the end of October. The AIDS Healthcare Foundation donated over $14 million in support of the proposition, making it the highest paying donor. The second highest donor supporting Proposition 61 was the California Nurses Association PAC, which donated $55,000. Ten major pharmaceutical companies donated between $4.5 million and $9.4 million each as of late October (California Proposition 61, 2016).
Implications for Nursing Politics, Policy, and Practice
Nurses know firsthand the consequences of lapses in patients' adherence to prescription medication regimes. We see it when patients with chronic illnesses such as congestive heart failure or diabetes return to hospitals with similar signs and symptoms as their initial admissions. We see it when patients in primary care settings can't afford to purchase medications and start to scrimp on dosages-taking half the prescribed amount and ending up with high blood pressure, undermedicated pain.
Nurses often answer the telephone or talk to patients who struggle to reach their physical and behavioral health potential because of not being able to complete their full course of medication or meet the objectives or benchmarks of their patient care plan.
Consider asking patients how they pay for prescription medications and what they do if they can't afford them. Ask other clinicians and social workers about their experience in this area. Demonstrate understanding of this issue from patients' and family members' perspectives to foster trust and patients' willingness to discuss these issues with you.
Stay informed about the issue by reading national newspapers and online resources from organizations such as AARP and the national nursing organizations involved with the issue. Communicate with your members of Congress and provide anecdotes about patients and your personal experiences. Follow the national bills on the government agenda; learn about PhRMA and its perspectives. Research opportunities abound, from exploring patient and clinician perspectives to analyzing policy gaps and the politics of the issue at state and national levels.
Leigh Purvis (Director, Health Services Research, AARP Public Policy Institute, Health Team) explained the importance of nurses and other clinicians being part of the policy discussions on prescription drug pricing:
Like all health care providers, I think nurses have a clear, vested interest in ensuring that their patients are able to access the medications they need to get and stay healthy. Unfortunately, recent prescription drug price trends are making it harder and harder for that to happen. (L. Purvis, personal e-mail communication, October 28, 2016) It's time for nursing organizations and nurses to join the national and state discussions on prescription drug costs and for nurses, individually, to be part of policy deliberations. We have much to offer and a window of opportunity for policy engagement.
